Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cleary

Showing results (391-400 of 445) with videos related to

Pageof 45
Sort By:
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.
Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
American Journal of Perinatology|August 25, 2022
The Association between Prenatal Nicotine Exposure and Offspring's Hearing ImpairmentErin M Cleary, Douglas A Kniss, Lida M Fette, et al.
The Oncologist|February 22, 2023
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic CancerKimberly Perez, Anna M Chiarella, James M Cleary, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JCO Precision Oncology|June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI CancerHarshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid TumorsPatricia M LoRusso, Jing Li, Angelika Burger, et al.
Pageof 45

Showing results (391-400 of 445) with videos related to

Sort By:
Pageof 45
Cancer Immunology Research|September 30, 2024
A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal CancerBrandon M Huffman, Osama E Rahma, Kevin Tyan, et al.
Cancer Discovery|March 15, 2014
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanibNikhil Wagle, Brian C Grabiner, Eliezer M Van Allen, et al.
American Journal of Perinatology|August 25, 2022
The Association between Prenatal Nicotine Exposure and Offspring's Hearing ImpairmentErin M Cleary, Douglas A Kniss, Lida M Fette, et al.
The Oncologist|February 22, 2023
Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic CancerKimberly Perez, Anna M Chiarella, James M Cleary, et al.
Nature|March 24, 2022
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancerKohei Shitara, Jaffer A Ajani, Markus Moehler, et al.
Cancer|March 27, 2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trialJames M Cleary, Nora K Horick, Nadine Jackson McCleary, et al.
JCO Precision Oncology|June 21, 2023
Highly Sensitive Circulating Tumor DNA Assay Aids Clinical Management of Radiographically Occult Isolated Peritoneal Metastases in Patients With GI CancerHarshabad Singh, Samuel J Klempner, Nelya Melnitchouk, et al.
Nature Communications|August 9, 2024
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinomaHarshabad Singh, Kristen E Lowder, Kevin Kapner, et al.
Lancet (London, England)|June 8, 2021
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialYelena Y Janjigian, Kohei Shitara, Markus Moehler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2016
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid TumorsPatricia M LoRusso, Jing Li, Angelika Burger, et al.
Pageof 45